Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.37 |
| ▸ | WNT1 | P04628 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.34 |
| ▸ | CLK2 | P49760 | 3/20 | 0.34 |
| ▸ | CLK3 | P49761 | 3/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252735 | 0.83 | CSNK1D (0.46) | CDC7WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL8256328 | 0.82 | CSNK1D (0.44) | CDC7WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL8255913 | 0.75 | WNT1 (0.36) | WNT1DYRK1ACLK2CLK3NMT1 | |
| SCHEMBL5377554 | 0.75 | CSNK1D (0.48) | WNT1DYRK1ACLK2CLK3NMT1 | |
| SCHEMBL5388950 | 0.72 | MAP2K4 (0.54) | WNT1DYRK1ACLK2CLK3MAP3K5 | |
| SCHEMBL5418834 | 0.72 | CSNK1D (0.37) | CDC7WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL5382977 | 0.71 | JAK2 (0.46) | CDC7WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL2471366 | 0.68 | GSK3B (0.47) | CDC7DYRK1AGSK3BGSK3A | |
| SCHEMBL8255894 | 0.67 | CSNK1D (0.64) | CDC7WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL5394703 | 0.64 | CSNK1D (0.53) | CDC7WNT1DYRK1ACLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CDC7 1480/4885WNT1 1359/4885DYRK1A 1188/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | CDC7 3422/4885WNT1 1364/4885DYRK1A 1932/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CDC7 1289/4885WNT1 255/4885DYRK1A 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.